Patient characteristics
| Patient no. . | Patient sex/age (y) . | Donor sex/age (y) . | Stage of CML at Dx/BMT . | Time from Dx to BMT (mo) . | Treatment pre BMT* . | HLA match . | Ablative regimen . | Infused CD3+ cells per kg . | IL-2 post-BMT . | GVHD grade in first y . | Time to cytogenetic relapse (mo) . | Time from BMT to DLI (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/25 | F/22 | BC/S | 5 | HDAC, Hy | 4/6 | Cy/TBI | 1.40E+06 | N | 1 | — | — |
| 2 | F/40 | M/39 | S/S | 5 | Hy | 6/6 | Cy/TBI | 5.36E+06 | N | 2 | 24 | 27 |
| 3 | F/52 | F/53 | S/S | 57 | IFN-α | 6/6 | Cy/TBI | 8.00E+05 | N | 0 | 37 | 40 |
| 4 | M/43 | F/45 | S/S | 7 | Hy | 6/6 | Cy/TBI | 1.13E+06 | Y | 0 | 34 | 57 |
| 5 | F/50 | F/40 | S/S | 9 | Hy | 6/6 | Cy/TBI | 1.20E+06 | Y | 1 | 11 | 33 |
| 6 | F/41 | M/35 | S/S | 12 | Hy | 5/6 | Cy/TBI | 1.60E+05 | Y | 0 | — | — |
| 7 | F/39 | M/47 | S/S | 23 | Hy | 6/6 | Cy/TBI | 7.00E+05 | Y | 0 | 6 | 24 |
| 8 | M/47 | M/39 | S/S | 55 | BMT, Hy | 6/6 | Bu/Cy | 6.00E+05 | Y | 0 | 11 | 38 |
| 9 | F/51 | F/52 | S/S | 3 | Hy | 6/6 | Cy/TBI | 1.55E+06 | N | 0 | 12 | 27 |
| 10 | F/57 | F/58 | S/S | 3 | Hy | 6/6 | Cy/TBI | 1.10E+06 | N | 0 | 13 | 18 |
| 11 | F/50 | F/46 | S/S | 12 | Hy, IFN-α | 6/6 | Cy/TBI | 2.45E+06 | N | 1 | 23 | 27 |
| 12 | M/30 | M/32 | S/S | 61 | BMT, Hy | 6/6 | Bu/Cy | 5.00E+06 | Y | 1 | — | — |
| 13 | M/24 | M/26 | AP/S | 7 | Hy, IFN-α | 6/6 | Cy/TBI | 1.65E+06 | Y | 0 | 27 | 42 |
| 14 | M/31 | F/29 | S/S | 17 | Bu, Hy | 6/6 | Cy/TBI | 3.00E+05 | Y | 0 | — | — |
| 15 | F/32 | M/34 | S/S | 9 | Hy | 6/6 | Cy/TBI | 1.00E+06 | Y | 0 | — | — |
| 16 | M/49 | M/40 | S/S | 5 | Hy | 6/6 | Cy/TBI | 3.19E+05 | Y | 0 | 24 | 27 |
| 17 | M/44 | M/45 | S/S | 5 | Hy | 6/6 | Cy/TBI | 3.90E+06 | N | 0 | 12 | 56 |
| 18 | M/33 | F/29 | S/S | 6 | Hy | 6/6 | Cy/TBI | 7.66E+05 | Y | 1 | 23 | 25 |
| Patient no. . | Patient sex/age (y) . | Donor sex/age (y) . | Stage of CML at Dx/BMT . | Time from Dx to BMT (mo) . | Treatment pre BMT* . | HLA match . | Ablative regimen . | Infused CD3+ cells per kg . | IL-2 post-BMT . | GVHD grade in first y . | Time to cytogenetic relapse (mo) . | Time from BMT to DLI (mo) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/25 | F/22 | BC/S | 5 | HDAC, Hy | 4/6 | Cy/TBI | 1.40E+06 | N | 1 | — | — |
| 2 | F/40 | M/39 | S/S | 5 | Hy | 6/6 | Cy/TBI | 5.36E+06 | N | 2 | 24 | 27 |
| 3 | F/52 | F/53 | S/S | 57 | IFN-α | 6/6 | Cy/TBI | 8.00E+05 | N | 0 | 37 | 40 |
| 4 | M/43 | F/45 | S/S | 7 | Hy | 6/6 | Cy/TBI | 1.13E+06 | Y | 0 | 34 | 57 |
| 5 | F/50 | F/40 | S/S | 9 | Hy | 6/6 | Cy/TBI | 1.20E+06 | Y | 1 | 11 | 33 |
| 6 | F/41 | M/35 | S/S | 12 | Hy | 5/6 | Cy/TBI | 1.60E+05 | Y | 0 | — | — |
| 7 | F/39 | M/47 | S/S | 23 | Hy | 6/6 | Cy/TBI | 7.00E+05 | Y | 0 | 6 | 24 |
| 8 | M/47 | M/39 | S/S | 55 | BMT, Hy | 6/6 | Bu/Cy | 6.00E+05 | Y | 0 | 11 | 38 |
| 9 | F/51 | F/52 | S/S | 3 | Hy | 6/6 | Cy/TBI | 1.55E+06 | N | 0 | 12 | 27 |
| 10 | F/57 | F/58 | S/S | 3 | Hy | 6/6 | Cy/TBI | 1.10E+06 | N | 0 | 13 | 18 |
| 11 | F/50 | F/46 | S/S | 12 | Hy, IFN-α | 6/6 | Cy/TBI | 2.45E+06 | N | 1 | 23 | 27 |
| 12 | M/30 | M/32 | S/S | 61 | BMT, Hy | 6/6 | Bu/Cy | 5.00E+06 | Y | 1 | — | — |
| 13 | M/24 | M/26 | AP/S | 7 | Hy, IFN-α | 6/6 | Cy/TBI | 1.65E+06 | Y | 0 | 27 | 42 |
| 14 | M/31 | F/29 | S/S | 17 | Bu, Hy | 6/6 | Cy/TBI | 3.00E+05 | Y | 0 | — | — |
| 15 | F/32 | M/34 | S/S | 9 | Hy | 6/6 | Cy/TBI | 1.00E+06 | Y | 0 | — | — |
| 16 | M/49 | M/40 | S/S | 5 | Hy | 6/6 | Cy/TBI | 3.19E+05 | Y | 0 | 24 | 27 |
| 17 | M/44 | M/45 | S/S | 5 | Hy | 6/6 | Cy/TBI | 3.90E+06 | N | 0 | 12 | 56 |
| 18 | M/33 | F/29 | S/S | 6 | Hy | 6/6 | Cy/TBI | 7.66E+05 | Y | 1 | 23 | 25 |
CML indicates chronic myelocytic leukemia; Dx, diagnosis; BMT, bone marrow transplantation; IL, interleukin; GVHD, graft-vs-host disease; DLI, donor lymphocyte infusion; BC, blast crisis; S, stable phase; AP, accelerated phase; HDAC, high-dose cytarabine; Hy, hydroxyurea; IFN-α, interferon α; Bu, busulfan; Cy, cyclophosphamide; and TBI, total body irradiation.